Successful targeting of ErbB2 receptors-is PTEN the key?

Abstract:

:Women with ErbB2-positive breast cancer have a poor prognosis, and frequently, chemotherapy treatment is ineffective. The ErbB2-targeted antibody trastuzumab improves survival when given with chemotherapy to patients with ErbB2-overexpressing metastatic disease, but treatment is not curative, and primary resistance is common. Postulated mechanisms of action for trastuzumab include immune-mediated cytotoxicity and receptor downmodulation. A study in this issue of Cancer Cell suggests that trastuzumab causes rapid activation of the PTEN lipid phosphatase, which in turn downregulates the phosphatidylinositol 3'-kinase (PI3K) pathway. Resistance to trastuzumab occurs when PTEN function is lost, suggesting that PTEN activation is a critical component of the therapeutic effect.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Crowder RJ,Lombardi DP,Ellis MJ

doi

10.1016/j.ccr.2004.08.001

keywords:

subject

Has Abstract

pub_date

2004-08-01 00:00:00

pages

103-4

issue

2

eissn

1535-6108

issn

1878-3686

pii

S1535610804002119

journal_volume

6

pub_type

评论,杂志文章
  • ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis.

    abstract::Inhibition of ERK-MAPK signaling by expression of dominant-negative MEK1 in the tumor vasculature suppresses angiogenesis and tumor growth. In an organotypic tissue culture angiogenesis assay, ERK-MAPK inhibition during the migratory phase results in loss of bipolarity, detachment, and cell death of isolated endotheli...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2005.12.021

    authors: Mavria G,Vercoulen Y,Yeo M,Paterson H,Karasarides M,Marais R,Bird D,Marshall CJ

    更新日期:2006-01-01 00:00:00

  • MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.

    abstract::The hypoxic tumor microenvironment serves as a niche for maintaining the glioma-initiating cells (GICs) that are critical for glioblastoma (GBM) occurrence and recurrence. Here, we report that hypoxia-induced miR-215 is vital for reprograming GICs to fit the hypoxic microenvironment via suppressing the expression of a...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2015.12.005

    authors: Hu J,Sun T,Wang H,Chen Z,Wang S,Yuan L,Liu T,Li HR,Wang P,Feng Y,Wang Q,McLendon RE,Friedman AH,Keir ST,Bigner DD,Rathmell J,Fu XD,Li QJ,Wang H,Wang XF

    更新日期:2016-01-11 00:00:00

  • Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.

    abstract::The childhood brain tumor, medulloblastoma, includes four subtypes with very different prognoses. Here, we show that paracrine signals driven by mutant β-catenin in WNT-medulloblastoma, an essentially curable form of the disease, induce an aberrant fenestrated vasculature that permits the accumulation of high levels o...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2016.03.002

    authors: Phoenix TN,Patmore DM,Boop S,Boulos N,Jacus MO,Patel YT,Roussel MF,Finkelstein D,Goumnerova L,Perreault S,Wadhwa E,Cho YJ,Stewart CF,Gilbertson RJ

    更新日期:2016-04-11 00:00:00

  • Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.

    abstract::The transcription factor Meis1 drives myeloid leukemogenesis in the context of Hox gene overexpression but is currently considered undruggable. We therefore investigated whether myeloid progenitor cells transformed by Hoxa9 and Meis1 become addicted to targetable signaling pathways. A comprehensive (phospho)proteomic ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2017.03.001

    authors: Mohr S,Doebele C,Comoglio F,Berg T,Beck J,Bohnenberger H,Alexe G,Corso J,Ströbel P,Wachter A,Beissbarth T,Schnütgen F,Cremer A,Haetscher N,Göllner S,Rouhi A,Palmqvist L,Rieger MA,Schroeder T,Bönig H,Müller-Tidow C

    更新日期:2017-04-10 00:00:00

  • Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all.

    abstract::A human pancreatic cancer progression model from intraepithelial neoplasia to ductal adenocarcinoma has been proposed. This process has been modeled in the mouse by activation of mutant Kras in pancreatic progenitor cells. In this issue of Cancer Cell, present a modification of their initial model by introducing a mut...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2005.04.025

    authors: Siveke JT,Schmid RM

    更新日期:2005-05-01 00:00:00

  • Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes.

    abstract::The telomere-stabilizing enzyme telomerase is induced in tumors and functionally associated with unlimited replicative potential. To further explore its necessity, transgenic mice expressing SV40 or HPV16 oncogenes, which elicit carcinomas in pancreas and skin, respectively, were rendered telomerase-deficient. Absence...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2004.08.032

    authors: Argilla D,Chin K,Singh M,Hodgson JG,Bosenberg M,de Solórzano CO,Lockett S,DePinho RA,Gray J,Hanahan D

    更新日期:2004-10-01 00:00:00

  • Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.

    abstract::Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease (MPD) initiated by expression of the p210-BCR-ABL fusion protein. We demonstrate in a murine model of p210-BCR-ABL-induced MPD that gene targeting of Rac1 and Rac2 significantly delays or abrogates disease development. Attenuation of the disease...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2007.10.015

    authors: Thomas EK,Cancelas JA,Chae HD,Cox AD,Keller PJ,Perrotti D,Neviani P,Druker BJ,Setchell KD,Zheng Y,Harris CE,Williams DA

    更新日期:2007-11-01 00:00:00

  • Determinants of oncogenic transformation in acute promyelocytic leukemia: the hetero-union makes the force.

    abstract::Acute promyelocytic leukemia (APL) is caused by chromosomal translocations that involve the retinoic acid receptor alpha (RAR) and several other genes to yield X-RAR fusion proteins. Unlike wild-type RARs, which require heterodimerization with the retinoid X receptor (RXR) for their function as DNA-binding transcripti...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章,评审

    doi:10.1016/j.ccr.2007.06.012

    authors: Minucci S,Pelicci PG

    更新日期:2007-07-01 00:00:00

  • The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

    abstract::Tumors constitute highly suppressive microenvironments in which infiltrating T cells are "exhausted" by inhibitory receptors such as PD-1. Here we identify TIGIT as a coinhibitory receptor that critically limits antitumor and other CD8(+) T cell-dependent chronic immune responses. TIGIT is highly expressed on human an...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2014.10.018

    authors: Johnston RJ,Comps-Agrar L,Hackney J,Yu X,Huseni M,Yang Y,Park S,Javinal V,Chiu H,Irving B,Eaton DL,Grogan JL

    更新日期:2014-12-08 00:00:00

  • A common pathway for genetic events leading to pheochromocytoma.

    abstract::Mutations in VHL, RET, NF1, SDHB, SDHC, and SDHD can give rise to pheochromocytoma/paraganglioma. These different genetic lesions may all act by decreasing the activity of a 2-oxoglutarate-dependent oxygenase, SM-20/EglN3/PHD3, resulting in reduced apoptosis of neural crest cells during development. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2005.07.012

    authors: Maxwell PH

    更新日期:2005-08-01 00:00:00

  • Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer.

    abstract::The TIGAR protein has antioxidant activity that supports intestinal tissue repair and adenoma development. Using a pancreatic ductal adenocarcinoma (PDAC) model, we show that reactive oxygen species (ROS) regulation by TIGAR supports premalignant tumor initiation while restricting metastasis. Increased ROS in PDAC cel...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2019.12.012

    authors: Cheung EC,DeNicola GM,Nixon C,Blyth K,Labuschagne CF,Tuveson DA,Vousden KH

    更新日期:2020-02-10 00:00:00

  • Defining UHRF1 Domains that Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties.

    abstract::UHRF1 facilitates the establishment and maintenance of DNA methylation patterns in mammalian cells. The establishment domains are defined, including E3 ligase function, but the maintenance domains are poorly characterized. Here, we demonstrate that UHRF1 histone- and hemimethylated DNA binding functions, but not E3 li...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2019.03.003

    authors: Kong X,Chen J,Xie W,Brown SM,Cai Y,Wu K,Fan D,Nie Y,Yegnasubramanian S,Tiedemann RL,Tao Y,Chiu Yen RW,Topper MJ,Zahnow CA,Easwaran H,Rothbart SB,Xia L,Baylin SB

    更新日期:2019-04-15 00:00:00

  • Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression.

    abstract::We used an experimental murine cancer metastasis model in which a colon adenocarcinoma cell line generates lung metastases, whose growth is stimulated in response to injection of bacterial lipopolysaccharide (LPS), to investigate the role of NF-kappaB in inflammation-induced tumor growth. We found that LPS-induced met...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2004.08.012

    authors: Luo JL,Maeda S,Hsu LC,Yagita H,Karin M

    更新日期:2004-09-01 00:00:00

  • Bcl-xL gain of function and p19 ARF loss of function cooperate oncogenically with Myc in vivo by distinct mechanisms.

    abstract::Overexpression of Bcl-xL, loss of p19 ARF, and loss of p53 all accelerate Myc oncogenesis. All three lesions are implicated in suppressing Myc-induced apoptosis, suggesting that this is a common mechanism by which they synergize with Myc. However, using an acutely switchable model of Myc-induced tumorigenesis, we demo...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2006.06.017

    authors: Finch A,Prescott J,Shchors K,Hunt A,Soucek L,Dansen TB,Swigart LB,Evan GI

    更新日期:2006-08-01 00:00:00

  • Using small molecules to overcome drug resistance induced by a viral oncogene.

    abstract::We used small molecule screening to discover compounds and mechanisms for overcoming E6 oncogene-mediated drug resistance. Using high-throughput screening in isogenic cell lines, we identified compounds that potentiate doxorubicin's lethality in E6-expressing colon cancer cells. Such compounds included quaternary ammo...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2006.01.012

    authors: Smukste I,Bhalala O,Persico M,Stockwell BR

    更新日期:2006-02-01 00:00:00

  • Sumoylation pathway is required to maintain the basal breast cancer subtype.

    abstract::The TFAP2C/AP-2γ transcription factor regulates luminal breast cancer genes, and loss of TFAP2C induces epithelial-mesenchymal transition. By contrast, the highly homologous family member, TFAP2A, lacks transcriptional activity at luminal gene promoters. A detailed structure-function analysis identified that sumoylati...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2014.04.008

    authors: Bogachek MV,Chen Y,Kulak MV,Woodfield GW,Cyr AR,Park JM,Spanheimer PM,Li Y,Li T,Weigel RJ

    更新日期:2014-06-16 00:00:00

  • Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.

    abstract::Our understanding of Ewing's sarcoma development mediated by the EWS/FLI fusion protein has been limited by a lack of knowledge regarding the tumor cell of origin. To circumvent this, we analyzed the function of EWS/FLI in Ewing's sarcoma itself. By combining retroviral-mediated RNA interference with reexpression stud...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2006.04.004

    authors: Smith R,Owen LA,Trem DJ,Wong JS,Whangbo JS,Golub TR,Lessnick SL

    更新日期:2006-05-01 00:00:00

  • Wnt breakers in colon cancer.

    abstract::Beta-catenin and Tcf4 are the downstream effectors of the Wnt signaling cascade. In colorectal cancer, mutations in Wnt cascade genes such as APC lead to the inappropriate formation of beta-catenin/Tcf4 complexes. Earlier work has predicted that disruption of the beta-catenin/Tcf4 protein-protein interaction could rev...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章,评审

    doi:10.1016/s1535-6108(03)00339-8

    authors: Clevers H

    更新日期:2004-01-01 00:00:00

  • Advancing the field of drug delivery: taking aim at cancer.

    abstract::Drug delivery systems for cancer therapeutics have now been used by millions of patients and have resulted in the creation of new therapies as well as significantly improving existing ones. Here we discuss a number of the drug delivery systems that have been approved by regulatory authorities and that are currently in...

    journal_title:Cancer cell

    pub_type: 杂志文章,评审

    doi:10.1016/s1535-6108(03)00276-9

    authors: Moses MA,Brem H,Langer R

    更新日期:2003-11-01 00:00:00

  • Opening a new GATAway for treating KRAS-driven lung tumors.

    abstract::In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition of GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These observations...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2012.04.032

    authors: Barbacid M

    更新日期:2012-05-15 00:00:00

  • ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.

    abstract::Amplification of 1q21 occurs in approximately 30% of de novo and 70% of relapsed multiple myeloma (MM) and is correlated with disease progression and drug resistance. Here, we provide evidence that the 1q21 amplification-driven overexpression of ILF2 in MM promotes tolerance of genomic instability and drives resistanc...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2017.05.011

    authors: Marchesini M,Ogoti Y,Fiorini E,Aktas Samur A,Nezi L,D'Anca M,Storti P,Samur MK,Ganan-Gomez I,Fulciniti MT,Mistry N,Jiang S,Bao N,Marchica V,Neri A,Bueso-Ramos C,Wu CJ,Zhang L,Liang H,Peng X,Giuliani N,Draetta G

    更新日期:2017-07-10 00:00:00

  • Glut3 Addiction: A Druggable Vulnerability in Glioblastoma.

    abstract::The link between GBM molecular subtype and response to treatment remains undefined. In this issue of Cancer Cell, Cosset and colleagues define a subpopulation of patients within the proneural/classical subtype sensitive to integrin blockade because of a Glut3 addiction. These findings reveal context-dependent druggabl...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2017.11.017

    authors: Bunda S,Zadeh G,Aldape KD

    更新日期:2017-12-11 00:00:00

  • Targeting the lncRNA SAMMSON Reveals Metabolic Vulnerability in Melanoma.

    abstract::In a recent study, Leucci et al. report a role for the long non-coding RNA SAMMSON in driving mitochondrial function in melanoma. Targeting SAMMSON, the gene of which is frequently co-amplified with MITF, highlights a new cell-type-specific therapeutic vulnerability in melanoma irrespective of BRAF, NRAS, or p53 statu...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2016.04.010

    authors: Goding CR

    更新日期:2016-05-09 00:00:00

  • Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.

    abstract::We elucidated genomic and transcriptomic changes that accompany the evolution of melanoma from pre-malignant lesions by sequencing DNA and RNA from primary melanomas and their adjacent precursors, as well as matched primary tumors and regional metastases. In total, we analyzed 230 histopathologically distinct areas of...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2018.06.005

    authors: Shain AH,Joseph NM,Yu R,Benhamida J,Liu S,Prow T,Ruben B,North J,Pincus L,Yeh I,Judson R,Bastian BC

    更新日期:2018-07-09 00:00:00

  • Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

    abstract::Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in 50% (22 of 44) of resistant BCCs and show that these mutations maintain Hedgehog signaling in the presence of SMO inhibitors. Alterations include four ligand ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccell.2015.02.002

    authors: Atwood SX,Sarin KY,Whitson RJ,Li JR,Kim G,Rezaee M,Ally MS,Kim J,Yao C,Chang AL,Oro AE,Tang JY

    更新日期:2015-03-09 00:00:00

  • β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.

    abstract::Malignant melanoma is characterized by frequent metastasis, however, specific changes that regulate this process have not been clearly delineated. Although it is well known that Wnt signaling is frequently dysregulated in melanoma, the functional implications of this observation are unclear. By modulating β-catenin le...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2011.10.030

    authors: Damsky WE,Curley DP,Santhanakrishnan M,Rosenbaum LE,Platt JT,Gould Rothberg BE,Taketo MM,Dankort D,Rimm DL,McMahon M,Bosenberg M

    更新日期:2011-12-13 00:00:00

  • Paradoxical Puma Prohibits Pyruvate Pumps to Prime Pathology.

    abstract::PUMA is a pro-apoptotic Bcl-2 family protein that can act as a tumor suppressor or oncogene in different cancers. In this issue, Kim et al. show that PUMA, independent of its apoptotic function, enforces glycolytic metabolism by inhibiting the transport of pyruvate into the mitochondria, promoting hepatocellular carci...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2019.01.016

    authors: Green DR

    更新日期:2019-02-11 00:00:00

  • Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer.

    abstract::In this issue of Cancer Cell, Nagaraja et al. dissect the molecular mechanisms underlying therapeutic responses to transcriptional disruptors in the fatal pediatric brain tumor, diffuse intrinsic pontine glioma (DIPG). Moreover, they identify super-enhancers mediating these effects, highlighting how normal brain devel...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccell.2017.04.008

    authors: Chheda MG,Gutmann DH

    更新日期:2017-05-08 00:00:00

  • Her 2 in 1.

    abstract::In this issue of Cancer Cell, Park et al. demonstrate that anti-erbB2 antibody primes adaptive immunity for increased tumor clearance and suggest that chemotherapy may in fact interfere with this process. ...

    journal_title:Cancer cell

    pub_type: 评论,杂志文章

    doi:10.1016/j.ccr.2010.07.009

    authors: Smyth MJ,Stagg J

    更新日期:2010-08-09 00:00:00

  • PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.

    abstract::Breast cancer is a heterogeneous disease and can be classified based on gene expression profiles that reflect distinct epithelial subtypes. We identify prostate-derived ETS factor (PDEF) as a mediator of mammary luminal epithelial lineage-specific gene expression and as a factor required for tumorigenesis in a subset ...

    journal_title:Cancer cell

    pub_type: 杂志文章

    doi:10.1016/j.ccr.2013.04.026

    authors: Buchwalter G,Hickey MM,Cromer A,Selfors LM,Gunawardane RN,Frishman J,Jeselsohn R,Lim E,Chi D,Fu X,Schiff R,Brown M,Brugge JS

    更新日期:2013-06-10 00:00:00